Table 1. Latest ACCF/AHA/HRS recommendations compared with ESC, ACCP, and CCS recommendations for the use of dabigatran in patients with non-valvular AF.

NOAC	ACCF/AHA/HRS	ESC	ACCP	CCS
Dabigatran	An alternative to warfarin in patients without prosthetic heart valves or hemodynamically significant valvular disease, renal failure, or advanced liver disease (impaired baseline clotting function); 150 mg twice daily in patients with CrCl >30 mL/min; 75 mg twice daily in patients with CrCl 15-30 mL/min (class I; level of evidence B)	NOACs in preference to warfarin (class IIa: level of evidence A) Dabigatran 150 mg bid for most patients; 110 mg bid for patients >80 years old, concomitant use of interacting drugs (e.g., verapamil), HAS-BLED score ≥3, or in patients with CrCl 30-49 mL/min (class IIa; level of evidence B)	150 mg bid rather than VKA, except for patients with AF and mitral stenosis, stent, or CHADS2 ≥1 who experience ACS (grade 2B)	NOACs in preference to VKAs Dabigatran 150 mg bid preferable to 110 mg bid, except in certain patients (e.g., patients with low body weight, decreased renal function, or at increased risk of major bleeding)

ACCF, American College of Cardiology Foundation; AHA, American Heart Association; HRS, Heart Rhythm Society; ESC, European Society of Cardiology; ACCP, American College of Chest Physicians; CCS, Canadian Cardiovascular Society; NOAC, novel oral anticoagulant; VKA, vitamin K antagonist.